» Articles » PMID: 35502428

Exploring Factors Influencing Medication Compliance in Saudi Rheumatoid Arthritis Patients: A Nationwide Cross-Sectional Survey - Results from the COPARA Study

Abstract

Purpose: Compliance is essential to achieve treatment goals in rheumatoid arthritis (RA) patients. The current study evaluated compliance and related factors in a large and diverse population.

Patients And Methods: Patients with RA who received active treatment were invited to participate in an online survey. The Arabic versions of the 5-Item Compliance Questionnaire for Rheumatology (ACQR-5) and the RA Impact of Disease (RAID) were used to measure compliance and disability, respectively. The patients were sub-grouped based on background disease-modifying anti-rheumatic drugs (DMARDs). Variables associated with high compliance were selected for the logistic regression analysis.

Results: A total of 1241 patients completed the survey and were included in the final analysis. Of those, 1055 (85%) were females with a mean (±SD) age and disease duration of 47.14 ± 13.71 and 8.77 ± 7.43 years, respectively. The mean RAID was 4.4±2.58, with 980 (79%) having an unacceptable level state. Patients with an unacceptable RAID level had a lower compliance rate (78.8% vs 85.8%, p = 0.001). Demographics associated with high compliance were female sex and increased age, with reported odds ratios of 1.018 (95% CI: 1.007-1.028) and 1.464 (95% CI: 1.016-2.108), respectively. Compliance was similar between patients on Janus kinase inhibitors or biological DMARDs (88.14% vs 80.83%, p = 0.17), between monotherapy, double therapy, or triple therapy recipients (80% vs 82.23% vs 81.32%, p = 0.665), and between patients receiving injectable and oral therapy (77.32% vs 81.14%, p = 0.246).

Conclusion: A high compliance level was observed in this population, with patient demographics influencing compliance rather than the medication type or route of administration. Interventional studies should focus on the of high-risk patients identified in this study.

Citing Articles

Exploring Patient Activation and Compliance in Patients with Different Rheumatological Disorders.

Almalag H, Alosaimi N, ALQahtani R, Alharbi R, Alarfaj A, Omair M Healthcare (Basel). 2025; 13(1.

PMID: 39791678 PMC: 11720284. DOI: 10.3390/healthcare13010071.


Predictors to Poor Quality of Life Among Patients with Heart Failure and Its Correlation with Their Medication Adherence: Finding for Healthcare Improvement and Follow-Up.

Alkubati S, Aleyadah H, Alboliteeh M, Alharbi A, Alsaif B, Alshammari B Patient Prefer Adherence. 2024; 18:2545-2557.

PMID: 39703933 PMC: 11656328. DOI: 10.2147/PPA.S503087.


A cross-sectional study of predictive factors of health literacy among rheumatoid arthritis patients in China.

Liu T, Meng W, Wang W, Sun G, Chen X, Lu Y Front Psychol. 2024; 15:1390442.

PMID: 38993349 PMC: 11236717. DOI: 10.3389/fpsyg.2024.1390442.


Exploring Impact of Multidisciplinary Care on Patient Activation in Saudi Rheumatoid Arthritis Patients: A Cross-Sectional Survey-Extended Results from the COPARA National Project.

Almalag H, Al Juffali L, Alshehri M, Altokhais N, Aljanobi G, Dessougi M J Multidiscip Healthc. 2023; 16:3455-3463.

PMID: 38024119 PMC: 10656861. DOI: 10.2147/JMDH.S436826.


Exploring factors influencing patient activation in Saudi rheumatoid arthritis patients: A Nationwide Cross-Sectional Survey-Results from the COPARA study.

Almalag H, Alshehri M, Altokhais N, Aljanobi G, Dessougi M, AlHarthi A Immun Inflamm Dis. 2023; 11(11):e1101.

PMID: 38018573 PMC: 10681035. DOI: 10.1002/iid3.1101.

References
1.
Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T . Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012; 14(3):R129. PMC: 3446510. DOI: 10.1186/ar3859. View

2.
Gossec L, Paternotte S, Aanerud G, Balanescu A, Boumpas D, Carmona L . Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011; 70(6):935-42. DOI: 10.1136/ard.2010.142901. View

3.
Curtis J, Bykerk V, Aassi M, Schiff M . Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. J Rheumatol. 2016; 43(11):1997-2009. DOI: 10.3899/jrheum.151212. View

4.
Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh D . Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis. 2016; 75(12):2080-2086. PMC: 5136699. DOI: 10.1136/annrheumdis-2015-208669. View

5.
Mena-Vazquez N, Manrique-Arija S, Yunquera-Romero L, Urena-Garnica I, Rojas-Gimenez M, Domic C . Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. Rheumatol Int. 2017; 37(10):1709-1718. DOI: 10.1007/s00296-017-3758-6. View